Cerevance's solengepras cuts Parkinson off-time by 0.6 hours in Phase 3, advancing toward FDA review

Cerevance, a spinout from Takeda, reported that a high 150‑mg dose of its Parkinson's drug solengepras reduced daily "off time" by an average of 0.61 hours compared with placebo in the Phase 3 ARISE trial. The reduction was observed as early as the second week of treatment.

The trial, which enrolled 341 patients with motor fluctuations, also showed that solengepras increased "on time" without dyskinesia, meeting a key secondary endpoint. Participants experienced less daytime sleepiness and reported improvements in quality of life, suggesting broader motor and non‑motor benefits.

Cerevance plans to meet with the FDA to discuss an approval pathway based on these results. The data were presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, Korea.